Managed Account Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Managed Account Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$82.7M	Buy	162,144 +21,928	+16%	+$10.7M	0.07%	299
2015 Q1	$63.3M	Buy	140,216 +65,630	+88%	+$27.8M	0.06%	357
2014 Q4	$30.6M	Buy	74,586 +3,863	+5%	+$1.52M	0.03%	530
2014 Q3	$25.5M	Buy	70,723 +3,734	+6%	+$1.25M	0.03%	586
2014 Q2	$18.9M	Sell	66,989 -51,265	-43%	-$15.2M	0.02%	701
2014 Q1	$35.5M	Buy	118,254 +354	+0.3%	+$109K	0.05%	433
2013 Q4	$32.5M	Sell	117,900 -21,322	-15%	-$6.13M	0.04%	452
2013 Q3	$43.6M	Buy	139,222 +11,183	+9%	+$2.94M	0.06%	335
2013 Q2	$28.8M	Buy	+128,039	New	+$29.8M	0.04%	443

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Managed Account Advisors's REGN Position: Q2 2015 in Review

Managed Account Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 16% in Q2 2015, buying an estimated $10.7M and bringing the position to 162,144 shares worth $82.7M. The position accounts for 0.07% of the portfolio, ranked #299.

Managed Account Advisors first reported a position in REGN in Q2 2013 and has held it in 9 quarters since. 541 funds tracked by Wall St. Rank hold REGN as of Q2 2015.

Managed Account Advisors held 162,144 shares of Regeneron Pharmaceuticals worth $82.7M as of Q2 2015.
Managed Account Advisors bought 21,928 Regeneron Pharmaceuticals shares in Q2 2015, an estimated $10.7M.
Regeneron Pharmaceuticals made up 0.07% of Managed Account Advisors's portfolio in Q2 2015, its #299 holding.
Managed Account Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 9 quarters since.
541 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.